Indegene — Q1 FY26 earnings call

Call held 6 Oct 2025

Management summary

Indegene's corporate update centered on the strategic acquisition of BioPharm to bolster its Brand Activation segment and omnichannel execution capabilities. The deal, valued at $104 million, integrates high-margin specialized marketing services and a massive proprietary HCP data engine. Management is focused on leveraging BioPharm's U.S. presence to cross-sell into Indegene's large pharma client base while targeting margin expansion through offshoring and data cost synergies.

Highlights

  • Announced acquisition of BioPharm, a U.S.-based omnichannel marketing business, for a total purchase price of $104 million.

  • Indegene reported FY25 revenue of $335 million, growing from approximately $10 million in 2010.

  • BioPharm recorded CY24 gross revenues of $38 million and net revenue of $29.2 million.

  • BioPharm's EBITDA for CY24 stood at $7.9 million, representing a healthy 27% margin on net revenue.

  • The acquisition expands Indegene's healthcare professional (HCP) data set from 1.8 million to 3 million profiles.

  • Transaction valued at approximately 9.8x 2024 EBITDA for the guaranteed portion, and 9x-9.5x including earn-outs.

  • Management expects the deal to be EPS accretive beyond the first 5-6 quarters.

  • Targeting $1 million in annual cost synergies post-integration.

Key financials

  1. Indegene FY25 Revenue $335 Mn
  2. BioPharm Net Revenue (CY24) $29.2 Mn
  3. BioPharm EBITDA (CY24) $7.9 Mn
  4. BioPharm EBITDA Margin 27%

What they filed

Q1 FY27: revenue up 33.2%, net profit up 33.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue282 287 267 256 307 +9%290 +1%368 +38%341 +33%
EBITDA46 52 40 37 71 +54%38 −27%103 +158%60 +62%
Net profit45 50 54 45 60 +33%35 −30%72 +33%60 +33%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • BioPharm (Target Entity)
    $38 Mn Gross Revenue53% Employee Costs (% of Net Revenue)20% Data & Tech Costs (% of Net Revenue)
  • Addressable Health (BioPharm Segment)
    $7.5 Mn CY24 Revenue

Guidance & targets

Profitability

  • EPS Accretion Profitability · FY27 · Medium confidence Accretive beyond 5-6 quarters
    We expect the deal to be EPS accretive beyond the first five to six quarters.

    — Suhas Prabhu, CFO

Margin

  • Combined EBITDA Margin Margin · next 6 quarters · Medium confidence 27-28%
    growth in the combined business should result in a 27% to 28% EBITDA on net revenue in around six quarters.

    — Suhas Prabhu, CFO

Other

  • Annual Cost Synergies Other · Annually · High confidence $1 million
    In terms of cost synergies, we expect around US $1 million annually, which should start accruing beyond the integration phase.

    — Suhas Prabhu, CFO

Revenue

  • Earn-out Growth Benchmark Revenue · CY25-CY26 · Medium confidence 15-20%
    achievement in the range of 15% to 20% growth year-on-year is what would result in the full payout of the earn-out.

    — Suhas Prabhu, CFO

Risks & concerns

  • Brand Budget Variability

    medium

    Brand budgets are more variable than enterprise engagements as they are tied to specific product lifecycles and FDA approvals.

    Management acknowledged

  • Integration and Immediate Earnings Impact

    medium

    Immediate impact on earnings due to transaction expenses ($0.8M), integration costs, and lower interest income from cash outflow.

    Management acknowledged

  • Regulatory Hurdles (FDA)

    low

    Analyst raised concerns about previous issues with FDA/regulatory hurdles deferring contracts; management plans to mitigate this by diversifying across a larger set of customers.

    Analyst acknowledged

Areas of evasion (1)

  • Specific historical benefits BioPharm gained from previous owner Omnicom were deflected as 'not a question for us to answer'.

Q&A highlights

3 direct
Client Concentration and Churn Direct
The customer concentration itself is about 80% for the top 20 customers, about 60% top 10 customers... customer engagements are running for 4 to 6 years.

Reveals the stability of the acquired revenue stream despite high concentration, which is typical for specialized pharma services.

Asked by Ahmed Madha, Unifi Capital

Margin Levers and Standalone Improvement Direct
One is data purchase itself... BioPharm purchase data from third-party, we purchase it. That itself is a lever... after that, with growth, we'll start adding more people, right, offshore.

Identifies specific operational efficiencies (data consolidation and offshoring) that will drive the targeted 27-28% EBITDA margin.

Asked by Chirag Kachhadiya, Motilal Oswal

Superior Margins with US-based Staff Direct
These are basically revenue augmentation solutions which help drive through HCP engagement, prescription uplift and revenue uptake. So that's the reason why we believe that these are better margin profile solutions.

Explains that BioPharm's high margins are driven by value-based pricing (outcomes) rather than time-and-material (input) models, justifying the acquisition price.

Asked by Ruchi Mukhija, ICICI Securities

2 min read 5 chapters

Detailed narrative

Strategic Acquisition of BioPharm

Indegene announced the acquisition of BioPharm, a U.S.-based omnichannel marketing specialist, for $104 million. This move significantly strengthens Indegene's 'Brand Activation' segment, allowing it to move from upstream content creation to downstream distribution. BioPharm brings a portfolio of 32+ active customers, including 17 of the top 25 global pharma companies, and has operated campaigns for 180 brands since 2023.

Financial Profile and Valuation

BioPharm is a high-margin business, recording a 27% EBITDA margin on $29.2 million net revenue in CY24. The deal is structured with a $65 million upfront payment, $12 million deferred to March 2026, and $27 million in performance-linked earn-outs for CY25 and CY26. The valuation multiple is pegged at 9x to 9.5x EBITDA, which management considers attractive given the specialized nature of the work and proprietary data assets.

Expansion of Data Assets and IP

A key driver of the deal is the integration of BioPharm's 'Tandem' platform with Indegene's 'Invisage'. This expands Indegene's HCP data set from 1.8 million to 3 million profiles, including high-value data in oncology, rare diseases, and ophthalmology. The combined data engine features 20+ years of promotional response data from 300 million exposure events, enhancing Indegene's ability to deliver precision marketing solutions.

Synergy Realization and Margin Outlook

Management identified $1 million in annual cost synergies, primarily from consolidating third-party data purchases and licensing costs. While the 100-person BioPharm team is currently U.S.-based, Indegene plans to drive future margin expansion by offshoring new roles to India. The combined entity is expected to stabilize at a 27-28% EBITDA margin within six quarters, despite a temporary dip during the integration phase.

Cross-Selling and Market Positioning

The acquisition addresses a gap in Indegene's brand-level relationships. While Indegene is strong at the centralized enterprise level, BioPharm has deep roots with individual brand owners in the U.S. Management reported immediate outreach from existing clients interested in the combined offering, signaling strong cross-sell potential for large-scale digital outreach models across mature product portfolios.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls